Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025
Vancouver / Jerusalem – November 13, 2025 – Shares of Clearmind Medicine Inc. (NASDAQ: CMND), a clinical‑stage psychedelic and neuroplastogen biotech company, jumped sharply on Thursday after the firm announced final approval to expand its FDA‑regulated Phase 1/2a clinical trial for Alcohol Use Disorder (AUD) to Hadassah Medical Center in Jerusalem. GlobeNewswire+1 At the same time, Clearmind filed a new Form 6‑K detailing a registered direct offering of shares and pre‑funded warrants, adding fresh capital but also raising dilution questions for investors. Stock Titan Below is a full breakdown of today’s key developments and what they mean for CMND stock.